Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today announced
updates on three of the Company’s key R&D pipeline programs, including
abicipar pegol (Anti-VEGF DARPin ® ), bimatoprost
sustained-release implant for glaucoma and SEMPRANA™ (dihydroergotamine)
inhalation aerosol (formerly referred to as LEVADEX ® ). In
addition, Allergan announced that it has received approval from the U.S.
Food and Drug Administration (FDA) for OZURDEX ®
(dexamethasone intravitreal implant) 0.7 mg as a treatment option for
diabetic macular edema (DME) in adult patients who have an artificial
lens implant (pseudophakic) or who are scheduled for cataract surgery
“Allergan has a long track record of delivering stockholder value by
efficiently investing in R&D to provide important new treatment options
to address unmet patient needs,” said David E.I.
for Allergan Announces R&D Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET investment picks